Skip to main content
Tuoxin Pharmaceutical Group Co.,Ltd. logo

Tuoxin Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 301089 ISIN · CNE100004YC3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 734 across all filing types
Latest filing 2024-10-24 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 301089

About Tuoxin Pharmaceutical Group Co.,Ltd.

https://www.tuoxinpharm.com

Tuoxin Pharmaceutical Group Co., Ltd. specializes in the research, development, production, and distribution of nucleosides and nucleotides. The company serves as a major global supplier of active pharmaceutical ingredients (APIs) and chemical intermediates. Its core product portfolio includes cytidine, inosine, guanosine, adenosine, and their various derivatives, which are essential components in the synthesis of antiviral, anti-tumor, and cardiovascular medications. Notably, the group provides key intermediates for drugs such as Ribavirin and Azvudine. Tuoxin Pharmaceutical leverages advanced synthetic biotechnology and large-scale manufacturing capabilities to support the global pharmaceutical industry. The company maintains a focus on technological innovation and quality control to ensure the stability and purity of its chemical products for diverse therapeutic applications.

Recent filings

Filing Released Lang Actions
中天国富证券有限公司关于拓新药业集团股份有限公司首次公开发行前已发行股份上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the listing and circulation of pre-IPO shares of a company (拓新药业集团股份有限公司). It discusses share issuance, lock-up commitments, shareholder commitments, shareholding structure changes, and compliance with regulatory requirements. It is not a financial report like an annual or interim report, nor is it a simple announcement. It is a formal verification opinion related to share issuance and listing compliance, which fits best under Capital/Financing Update (CAP) as it relates to share issuance and listing matters. The document length is 4600 characters, which is substantive and contains detailed information, not just an announcement or certification. Therefore, the classification is CAP with high confidence.
2024-10-24 Chinese
关于子公司拓新药业医学检验（河南）有限公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the completion of business registration and obtaining a business license for a newly established subsidiary company. It includes details about the subsidiary's registration, legal representative, capital, and business scope. There is no financial data, no mention of financial results, no regulatory certifications, or meeting materials. It is not a report or a financial filing but a corporate announcement about a subsidiary's registration status. This fits best under Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories.
2024-09-26 Chinese
第五届董事会第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at the company's fifth board of directors' second meeting. It includes details about the meeting's convening, attendance, and voting results on various corporate matters such as approval of the 2024 semi-annual report, fundraising usage report, related party transactions, establishment of a subsidiary, project adjustments, and stock incentive plan changes. The document does not contain the actual semi-annual report or financial statements but refers to them being disclosed elsewhere (on the cninfo website). The document is relatively short (2486 characters) and serves as a meeting resolution announcement rather than a full financial report or detailed management discussion. It primarily concerns board decisions and approvals, which fits the category of Board/Management Information (MANG).
2024-08-23 Chinese
第五届监事会第二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of the company 拓新药业集团股份有限公司 regarding their second meeting of the fifth session. It includes voting results on several agenda items such as approval of the 2024 semi-annual report, fundraising usage report, related party transactions, investment project adjustments, and stock incentive plan matters. The document references the 2024 semi-annual report and other detailed announcements published separately on the stock exchange information website, indicating this document itself is not the full semi-annual report but a meeting resolution and announcement of decisions. The document length is about 2024 characters, relatively short, and it mainly reports meeting resolutions and voting outcomes. This fits the category of a regulatory announcement of meeting resolutions rather than the full interim report or financial statements. Therefore, the best fitting classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other more specific categories like Interim Report (IR) or Annual Report (10-K).
2024-08-23 Chinese
关于预计2024年日常性关联交易的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the company's expected related party transactions for the year 2024. It includes details about the nature of the transactions, the related parties involved, pricing principles, and approvals by the board and independent directors. It does not contain financial statements or comprehensive financial performance data. The document is a regulatory announcement about related party transactions, which fits best under Regulatory Filings (RNS) as it does not qualify as a full financial report or other specific categories like Board/Management changes or Capital updates.
2024-08-23 Chinese
中天国富证券有限公司关于拓新药业集团股份有限公司2024年半年度持续督导跟踪报告
Regulatory Filings Classification · 95% confidence The document is titled as a '2024 half-year continuous supervision tracking report' by a sponsoring institution for a company. It details the sponsor's review and supervision activities over the half-year period, including information disclosure, governance, fundraising supervision, and compliance with commitments. The document is a report on ongoing monitoring and supervision rather than a full financial report or earnings release. It contains no financial statements or detailed financial analysis typical of Interim/Quarterly Reports (IR) or Annual Reports (10-K). It is also not an announcement or a brief notice but a substantive report on supervision activities. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general regulatory compliance and supervision report that does not fit other specific categories.
2024-08-23 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.